EP 3505174 B1 20200429 - DEOXYNUCLEOSIDE THERAPY FOR DISEASES CAUSED BY UNBALANCED NUCLEOTIDE POOLS INCLUDING MITOCHONDRIAL DNA DEPLETION SYNDROMES
Title (en)
DEOXYNUCLEOSIDE THERAPY FOR DISEASES CAUSED BY UNBALANCED NUCLEOTIDE POOLS INCLUDING MITOCHONDRIAL DNA DEPLETION SYNDROMES
Title (de)
DEOXYNUKLEOSIDTHERAPIE FÜR DURCH UNAUSGEGLICHENE NUKLEOTIDPOOLS VERURSACHTE ERKRANKUNGEN, EINSCHLIESSLICH MITOCHONDRIALER DNA-DEPLETIONSSYNDROME
Title (fr)
THÉRAPIE DÉSOXYNUCLÉOSIDE POUR MALADIES PROVOQUÉES PAR DES RÉSERVES DE NUCLÉOTIDE NON ÉQUILIBRÉES COMPRENANT DES SYNDROMES DÉPLÉTION D'ADN MITOCHONDRIAL
Publication
Application
Priority
- US 201562180914 P 20150617
- EP 16812537 A 20160617
- US 2016038110 W 20160617
Abstract (en)
[origin: WO2016205671A1] The invention relates generally to a pharmacological therapy for human genetic diseases, specifically those characterized by unbalance nucleotide pools, more specifically mitochondrial DNA depletion syndromes, and more specifically, thymidine kinase 2 (TK2) deficiency. The pharmacological therapy involves the administration of at least one deoxynucleoside, or mixtures thereof. For the treatment of TK2 deficiency, the pharmacological therapy involves the administration of either deoxythymidine (dT) or deoxycytidine (dC), or mixtures thereof. This administration of deoxynucleosides is applicable to other disorders of unbalanced nucleotide pools, especially those found in mitochondrial DNA depletion syndrome.
IPC 8 full level
A61K 31/7068 (2006.01); A61K 31/513 (2006.01); A61K 31/7064 (2006.01); A61K 31/7072 (2006.01); A61K 31/7076 (2006.01); A61K 31/708 (2006.01); A61P 21/00 (2006.01); A61P 43/00 (2006.01)
CPC (source: CN EP IL KR RU US)
A61K 9/0053 (2013.01 - IL US); A61K 31/513 (2013.01 - EP IL US); A61K 31/7068 (2013.01 - CN EP IL KR RU US); A61K 31/7072 (2013.01 - CN EP IL KR RU US); A61K 31/7076 (2013.01 - CN EP IL KR US); A61K 31/708 (2013.01 - CN EP IL KR US); A61K 45/06 (2013.01 - IL US); A61K 48/00 (2013.01 - KR RU); A61P 21/00 (2018.01 - CN EP IL KR US); A61P 43/00 (2018.01 - CN EP IL KR US); C12Q 1/6827 (2013.01 - RU); G01N 33/50 (2013.01 - RU); A61K 2300/00 (2013.01 - IL)
C-Set (source: EP US)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
DOCDB simple family (publication)
WO 2016205671 A1 20161222; WO 2016205671 A9 20180104; AU 2016280293 A1 20180208; AU 2016280293 B2 20200702; AU 2020204042 A1 20200709; AU 2020204042 B2 20210715; AU 2021250841 A1 20211104; AU 2021250841 B2 20230209; BR 112017027079 B1 20210427; BR 122020021913 B1 20210706; CA 2989653 A1 20161222; CN 107847512 A 20180327; CN 116726035 A 20230912; CY 1122605 T1 20210312; CY 1123107 T1 20211029; DK 3310362 T3 20191007; DK 3505174 T3 20200713; EP 3310362 A1 20180425; EP 3310362 A4 20181219; EP 3310362 B1 20190828; EP 3505174 A1 20190703; EP 3505174 B1 20200429; EP 3569236 A1 20191120; ES 2748556 T3 20200317; ES 2808148 T3 20210225; HK 1252133 A1 20190517; HR P20191794 T1 20200207; HR P20200949 T1 20201002; HU E046399 T2 20200330; HU E050678 T2 20201228; IL 256331 A 20180228; IL 256331 B 20200831; IL 275255 A 20200730; IL 275255 B 20210429; IL 275256 A 20200730; IL 275256 B1 20230501; IL 275256 B2 20230901; JP 2018521993 A 20180809; JP 2020019791 A 20200206; JP 2020019792 A 20200206; JP 6599484 B2 20191030; JP 6675037 B2 20200401; JP 7036782 B2 20220315; KR 20180039624 A 20180418; KR 20220018623 A 20220215; LT 3310362 T 20191111; LT 3505174 T 20200910; MX 2017016425 A 20181211; MX 2020000269 A 20220103; PL 3310362 T3 20200430; PL 3505174 T3 20200824; PT 3310362 T 20191029; PT 3505174 T 20200706; RS 59724 B1 20200131; RS 60572 B1 20200831; RU 2018101305 A 20190717; RU 2018101305 A3 20191031; RU 2020112901 A 20200605; RU 2721492 C2 20200519; SI 3310362 T1 20200228; SI 3505174 T1 20210226; US 10471087 B2 20191112; US 11110111 B2 20210907; US 11666592 B2 20230606; US 2018133241 A1 20180517; US 2020038424 A1 20200206; US 2021244754 A1 20210812; US 2023277577 A1 20230907
DOCDB simple family (application)
US 2016038110 W 20160617; AU 2016280293 A 20160617; AU 2020204042 A 20200617; AU 2021250841 A 20211011; BR 112017027079 A 20160617; BR 122020021913 A 20160617; CA 2989653 A 20160617; CN 201680045355 A 20160617; CN 202310757609 A 20160617; CY 191101127 T 20191030; CY 201100578 T 20200625; DK 16812537 T 20160617; DK 19156021 T 20160617; EP 16812537 A 20160617; EP 19156021 A 20160617; EP 19178700 A 20160617; ES 16812537 T 20160617; ES 19156021 T 20160617; HK 18111524 A 20180907; HR P20191794 T 20191003; HR P20200949 T 20200615; HU E16812537 A 20160617; HU E19156021 A 20160617; IL 25633117 A 20171214; IL 27525520 A 20200609; IL 27525620 A 20200609; JP 2017566000 A 20160617; JP 2019182191 A 20191002; JP 2019182192 A 20191002; KR 20187001496 A 20160617; KR 20227002790 A 20160617; LT 16812537 T 20160617; LT 19156021 T 20160617; MX 2017016425 A 20160617; MX 2020000269 A 20160617; PL 16812537 T 20160617; PL 19156021 T 20160617; PT 16812537 T 20160617; PT 19156021 T 20160617; RS P20191295 A 20160617; RS P20200779 A 20160617; RU 2018101305 A 20160617; RU 2020112901 A 20160617; SI 201630439 T 20160617; SI 201630830 T 20160617; US 201615736092 A 20160617; US 201916583852 A 20190926; US 202117242822 A 20210428; US 202318138432 A 20230424